PLA2G4A and leukemia: Thus, we treated leukemia cell lines THP1, U937, and HL60 with PLA2G4A inhibitor AACOCF3, an analog of arachidonic acid that inhibits the PLA2G4A phospholipase activity by competing for the active catalytic site.